RMD Add to watchlist
$224.84 +4.79 (+2.18%)
After Hours: $224.84 +0.00 (+0.00%)
Last updated: Aug 11, 2026 20:24
52-Week Range
$224.84
$180.27 $224.84 $293.81

Fundamentals Overview

ResMed Inc. is in the middle of its 52-week range with premium valuation, trending upward today.

Valuation premium

P/E 21.4 PEG 2.45 P/B 4.94 P/S 5.77

Intrinsic value (DCF)

+77.4% upside vs price

Profitability

Net margin 26.9%

Risk (Beta)

0.75 — lower vol

Earnings & growth

EPS $10.51 Rev +2.3% Profit -3.8% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 59% confidence Risk: Lower Volatility — Beta 0.75. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +77.4% upside vs price · Analyst grade: A

Pressures (Sell):

Sentiment weakening (3 downgrades) · 3M vs Healthcare sector: -8.3%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$32.61B
P/E (TTM)
21.4
EPS (TTM)
$10.51
Dividend Yield
1.07%
52-Week Range
$180.27 - $293.81
Volume vs Avg
N/A
Beta
0.75

About

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and per...
Sector: Healthcare
Headquarters: US
Employees: 10,600
IPO Date: Jun 1995
Beta: 0.75 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: A. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 4, Equal Weight: 4, Hold: 4, Neutral: 4, Outperform: 9, Overweight: 5.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $398.81; current price is $224.84. That’s a +77.4% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 21.4
DCF value (model) $398.81 (77.4% upside)
PEG (TTM) 2.45
P/B (TTM) 4.94
P/S (TTM) 5.77
P/FCF (TTM) 11.29
Liquidity & enterprise
Current Ratio (TTM) 3.1
Quick Ratio (TTM) 2.42
Cash Ratio (TTM) 1.05
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 26.94%
Gross margin (TTM) 61.16%
Operating margin (TTM) 33.48%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for RMD.

Analyst Sentiment at a Glance

A Sentiment Weakening
Buy 4Equal Weight 4Hold 4Neutral 4Outperform 9Overweight 5
0 upgrades, 3 downgrades
Price Target Consensus
Current $224.84
Median $230.00
Consensus $239.67
Low consensus $213.00
High consensus $300.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Mizuho maintain Outperform Outperform 2026-07-15
Citigroup downgrade Buy Neutral 2026-07-13
Jefferies maintain Hold Hold 2026-07-10
RBC Capital maintain Outperform Outperform 2026-07-08
Wells Fargo maintain Equal Weight Equal Weight 2026-07-08
Keybanc maintain Overweight Overweight 2026-06-22
Morgan Stanley downgrade Overweight Equal Weight 2026-06-17
Citigroup maintain Buy Buy 2026-06-15
Wells Fargo maintain Equal Weight Equal Weight 2026-05-01
RBC Capital maintain Outperform Outperform 2026-05-01
Keybanc maintain Overweight Overweight 2026-04-27
Citigroup maintain Buy Buy 2026-04-09
Citigroup maintain Buy Buy 2026-02-02
Piper Sandler maintain Neutral Neutral 2026-01-30
Wells Fargo maintain Equal Weight Equal Weight 2026-01-30
RBC Capital maintain Outperform Outperform 2026-01-30
Stifel maintain Hold Hold 2026-01-30
Stifel maintain Hold Hold 2025-12-18
Baird downgrade Outperform Neutral 2025-12-16
Baird maintain Outperform Outperform 2025-11-03
Mizuho maintain Outperform Outperform 2025-10-31
Keybanc maintain Overweight Overweight 2025-10-31
RBC Capital maintain Outperform Outperform 2025-10-31
Morgan Stanley maintain Overweight Overweight 2025-10-21
Keybanc maintain Overweight Overweight 2025-08-01
UBS maintain Buy Buy 2025-08-01
Mizuho maintain Outperform Outperform 2025-08-01
Stifel maintain Hold Hold 2025-08-01
RBC Capital maintain Outperform Outperform 2025-08-01
Piper Sandler maintain Neutral Neutral 2025-08-01